Bavarian Nordic, a biotechnology company, agreed to acquire the travel vaccine portfolio of Emergent BioSolutions, a developer of vaccines, for $380m. “This acquisition adds not only to our commercial portfolio and reinforces our leading position in travel vaccines, but it also strengthens our pipeline," Paul Chaplin, Bavarian Nordic President and CEO.